Daily Cardiology Research Analysis
Three studies stand out today in cardiology: a 6-year extension of the STEP randomized trial confirms sustained benefits of intensive blood pressure control in older hypertensive patients; a network meta-analysis of 12 RCTs supports complete revascularization—especially physiology-guided—for multivessel disease in acute MI; and a large multi-cohort study links chronic kidney disease to increased long-term sudden cardiac death risk, identifying proteomic markers that may refine risk stratificatio
Summary
Three studies stand out today in cardiology: a 6-year extension of the STEP randomized trial confirms sustained benefits of intensive blood pressure control in older hypertensive patients; a network meta-analysis of 12 RCTs supports complete revascularization—especially physiology-guided—for multivessel disease in acute MI; and a large multi-cohort study links chronic kidney disease to increased long-term sudden cardiac death risk, identifying proteomic markers that may refine risk stratification.
Research Themes
- Intensive blood pressure targets in elderly hypertension
- Revascularization strategies in multivessel acute myocardial infarction
- CKD-associated sudden cardiac death risk and proteomic biomarkers
Selected Articles
1. Intensive Blood Pressure Control in Older Patients With Hypertension: 6-Year Results of the STEP Trial.
In a 6.11-year median follow-up of 8,511 older hypertensive patients, sustained intensive SBP control (110–<130 mm Hg) reduced the composite cardiovascular outcome versus delayed intensive control (HR 0.82). Parametric g-formula analyses indicated the greatest benefit when intensive therapy was initiated at randomization, with attenuated benefit if delayed. Hypotension occurred more often with sustained intensive treatment, while other safety outcomes were similar.
Impact: This high-quality randomized trial with extended follow-up provides robust evidence that early and sustained intensive BP control confers durable cardiovascular benefit in older adults.
Clinical Implications: For older hypertensive patients who can tolerate it, initiate and sustain intensive SBP targets early to maximize cardiovascular risk reduction, with vigilance for hypotension.
Key Findings
- Median 6.11-year follow-up: sustained intensive SBP control lowered primary composite events vs delayed intensive (HR 0.82; 95% CI 0.71–0.96).
- Greatest benefit when intensive treatment was initiated at randomization (RR 0.83); benefit attenuated when initiation was delayed by 12 months (RR 0.88).
- Hypotension was more frequent with sustained intensive control; other safety outcomes were similar.
Methodological Strengths
- Randomized controlled design with extended follow-up
- Advanced causal methods (Fine-Gray model and parametric g-formula) to assess timing effects
Limitations
- Increased hypotension risk with intensive targets
- Generalizability primarily to the studied population and care settings; adherence and treatment protocols may differ elsewhere
Future Directions: Define patient subgroups balancing hypotension risk vs benefit; test implementation strategies for early initiation; assess cognitive and renal outcomes under sustained intensive control.
BACKGROUND: The STEP (Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients) trial showed that intensive systolic blood pressure (SBP) control reduced cardiovascular risk. OBJECTIVES: Study investigators conducted an extended follow-up of the STEP trial to determine the longer-term effects of intensive blood pressure (BP) control. METHODS: In this randomized controlled trial, 8,511 patients with hypertension were randomly assigned to the intensive treatment group, with an SBP target of 110 mm Hg to <130 mm Hg, or the standard treatment group, with an SBP target of 130 mm Hg to <150 mm Hg. After the original trial ended, all surviving patients, either in the standard group or the intensive treatment group previously, received intensive treatment in the extended period, referred to as the delayed intensive treatment group or the sustained intensive treatment group. The primary outcome was a composite of stroke, acute coronary syndrome, acute decompensated heart failure, coronary revascularization, atrial fibrillation, or death resulting from cardiovascular causes. The Fine-Gray subdistribution hazard model was used to estimate the HR between the 2 groups, and g-formula methods were initiated to compare overall primary outcome risks with intensive treatment initiated from randomization and initiated every year after randomization. RESULTS: After a median follow-up of 6.11 years, the mean SBP was 127.9 mm Hg in the sustained intensive treatment group and 129.5 mm Hg in the delayed intensive treatment group. The incidence rate of primary outcome was 1.12% per year in the sustained intensive treatment group, compared with 1.33% per year in the delayed intensive treatment group (HR: 0.82; 95% CI: 0.71-0.96). No difference in safety event rates between the 2 groups was observed except for hypotension, which occurred more frequently in the sustained intensive treatment group. Furthermore, analyses using the parametric g-formula showed that compared with the standard BP treatment, intensive treatment initiating from randomization (0 month) yielded the greatest benefit (relative risk [RR]: 0.83; 95% CI: 0.70-0.96), with an attenuated cardiovascular benefit for later initiation from 12 months (RR: 0.88; 95% CI: 0.76-0.99). CONCLUSIONS: Our results suggested that sustained intensive BP control could benefit patients with hypertension compared with delayed intensive treatment in the longer-term follow-up. The earlier intensive treatment is initiated after the hypertension diagnosis, the greater the cardiovascular benefits will be. (Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients [STEP]; NCT03015311).
2. Myocardial infarction and multivessel disease: a network meta-analysis comparing complete functional, angiography-guided and culprit only revascularization.
Across 12 randomized trials (n=11,581), complete revascularization reduced repeat revascularization versus culprit-only strategies; physiology-guided complete PCI also reduced cardiovascular death (IRR 0.61). Reductions in spontaneous MI were not statistically significant.
Impact: This synthesis strengthens the evidence base for complete revascularization in acute MI with multivessel disease and highlights incremental survival benefit when physiology guides non-culprit PCI.
Clinical Implications: Favor a complete revascularization strategy in appropriate MI patients with multivessel disease, using physiology guidance to prioritize non-culprit lesion treatment where feasible.
Key Findings
- Physiology-guided complete PCI reduced cardiovascular death vs culprit-only PCI (IRR 0.61; 95% CI 0.39–0.96).
- Both physiology-guided and angiography-guided complete PCI reduced repeat revascularization vs culprit-only (IRR 0.37 and 0.33, respectively).
- Spontaneous MI reductions with complete strategies were not statistically significant.
Methodological Strengths
- Network meta-analysis restricted to randomized clinical trials
- Frequentist framework with incidence rate ratios enabling indirect comparisons
Limitations
- Heterogeneity in trial eras, PCI techniques, and timing of non-culprit intervention
- Patient-level data were not available to refine subgroup effects
Future Directions: Randomized trials comparing physiology-guided vs imaging-guided complete strategies, optimal timing (index vs staged), and patient-centered outcomes including quality of life.
BACKGROUND: The optimal percutaneous coronary intervention (PCI) revascularization strategy in patients presenting with multi-vessel (MV) coronary artery disease (CAD) and acute myocardial infarction (MI) has not been systematically addressed. Accordingly, we performed a frequentist network meta-analysis with the aim of assessing the prognostic impact of different PCI strategies. METHODS: We conducted an electronic research for studies including angiography-guided and functional-guided complete revascularization in patients with acute MI from 2001 to 30 RESULTS: Twelve randomized clinical trials involving 11,581 patients fulfilled the inclusion criteria. Functional-guided complete PCI was associated with lower cardiovascular death compared to culprit-only PCI (incidence rate ratio [IRR] 0.61, 95% confidence interval [CI] 0.39-0.96; P=0.033). Both complete functional- and angio-guided PCI reduced the risk of further revascularization compared to culprit-only PCI (IRR 0.37, 95% CI 0.24-0.55, P<0.001, and IRR 0.33, 95% CI 0.20-0.52, P<0.001, respectively). Both complete functional- and angio-guided PCI resulted in a non-significant reduction of spontaneous MI compared to culprit-only PCI strategy (IRR 0.76, 95% CI 0.50-1.15; P=0.20 and IRR 0.72, 95% CI 0.47-1.12; P=0.15, respectively). No significant differences were found regarding other study endpoints and other comparisons. CONCLUSIONS: In patients with MI and MV CAD, undergoing successful PCI of IRA, a complete revascularization strategy, regardless of the specific approach, was associated with a lower incidence of repeat revascularization compared with a culprit-only strategy. Complete functional-guided revascularization resulted in lower incidence of cardiovascular death, whereas a complete angio-guided approach did not show the same benefit.
3. Chronic kidney disease is associated with increased risk of sudden cardiac death.
Across large population cohorts, CKD—including early stages—was associated with higher long-term sudden cardiac death risk. Proteomic analyses identified five candidate proteins (NTproBNP, ANGPT2, FGF23, DTNB, SEPTIN8) associated with SCD in CKD, pointing to potential biomarkers or mechanistic pathways.
Impact: This multi-cohort study elevates SCD prevention priorities in CKD and introduces proteomic candidates that could refine risk stratification and therapeutic targeting.
Clinical Implications: In CKD patients, consider enhanced arrhythmic risk assessment and integrated cardio-renal management; emerging protein markers may inform future SCD risk models.
Key Findings
- CKD was associated with increased long-term SCD risk across UK Biobank and Changsha cohorts.
- Elevated SCD risk was evident from early-stage CKD and increased with advanced stages.
- Proteomic analyses identified NTproBNP, ANGPT2, FGF23, DTNB, and SEPTIN8 as candidate proteins linked to SCD in CKD.
Methodological Strengths
- Use of multiple large-scale, population-based cohorts
- Proteomic validation across independent datasets (UK Biobank, Framingham Offspring)
Limitations
- Observational design with residual confounding risk
- Limited mechanistic validation; protein markers require prospective clinical qualification
Future Directions: Develop and validate SCD risk scores tailored to CKD incorporating proteomic markers; test preventive strategies (e.g., medical therapy, monitoring) in high-risk CKD subgroups.
Patients with chronic kidney disease (CKD) are recognized as a higher risk group for cardiovascular disease (CVD) due to various traditional risk factors, kidney-specific factors, and comorbidities, which have recently attracted significant attention. However, the long-term risk of acute CVD events such as sudden cardiac death (SCD) in CKD patients is unclear. Using the UK Biobank and Changsha cohorts, we find that CKD is associated with an increased risk of SCD. Patients with early-stage CKD, especially those with advanced CKD, faced an elevated risk of SCD. Furthermore, through proteomic analyses of the UK Biobank and Framingham Offspring Cohort, we identify five candidate proteins (NTproBNP, ANGPT2, FGF23, DTNB, and SEPTIN8) linked to SCD risk in CKD patients. Here, we show that patients with CKD have an increased risk of SCD in the long term, underscoring the imperative for strategies that address both cardiovascular risk and renal function in this population.